GlycanDx-MODY - a glycomics precision diagnostic assay for MODY diabetes

GlycanDx-MODY是一种用于识别hnf1a型成熟型糖尿病（MODY）患者的检测方法。这是一种影响高达4%的糖尿病患者（在英国有40K-160K病例）的糖尿病，可以用廉价的口服药物治疗。大多数MODY患者都被误诊，并被开了胰岛素，这不仅不能治疗他们的疾病，而且很不方便，也很昂贵。从长远来看，患者患失明、肾病和心脏病的风险更高。有一些基因测试是可行的，但它们并没有被全科医生广泛使用，因为它们太贵了，而且结果很难解释。这是一个由牛津生物科学公司Ludger领导的合作项目，以及非资助合作伙伴Genos（欧洲中小企业）和OCDEM（牛津糖尿病研究小组）。在一项对200名糖尿病患者的研究中，该测试阳性地识别出那些患有HNF1A-MODY的患者。该检测价格实惠（仅为基因检测价格的四分之一），检测速度快（3天左右），检测结果易于解读。我们希望进一步发展这种检测方法作为常规临床诊断或筛查工具。这项可行性研究是为了规划下一阶段的开发和商业化测试，这将产生一个蓝图，以有效地推进项目，造福患者。

GlycanDx-MODY is a test to identify patients with HNF1A-type Maturity Onset Diabetes of the Young (MODY). This is a type of diabetes affecting up to 4% of diabetics (40K-160K cases in the UK) that can be treated with inexpensive oral drugs. Most MODY patients are misdiagnosed and prescribed insulin, which does not treat their disease, is inconvenient and expensive. In the long term, patients have a higher risk of blindness, kidney disease and heart disease. There are genetic tests available, but they are not widely used by GPs because they are too expensive and the results are difficult to interpret. This is a collaborative project led by Ludger, an Oxford based bioscience company, along with non-funded partners Genos (European SME) and OCDEM (Oxford diabetes research group). In a study of 200 diabetes patients the test positively identified those with HNF1A-MODY. The test is affordable (quarter of the price of genetic tests), quick (~ 3 days turnaround) and the results are easy to interpret. We would like to further develop this assay for routine clinical use as a diagnostic or screening tool. This Feasiblity Study is to plan the next stage in development and commercialisation of the test which will result in a blueprint to progress the project efficiently for the benefit of patients.